This thesis explores the pathomechansim of inflammation and the usage of selective COX2 inhibitors. Mainly a high risk of pro-thrombotic events has been found to be related to their administration. Therefore alternative treatments for high-risk patients not suitable for using COX2 inhibitors is also being investigated. The clinical relevance and safety challenges with the usage of COX2 inhibitors is controversial. Therefore development of new COX2 inhibitors with an increased safety profile is being under development for the future.